Alzheimer's disease is the most prevalent form of dementia. However, it still remains difficult to diagnose. Several biomarkers have been proposed to detect the onset of the disease and follow the pathological evolution of patients, but it is still difficult to have clear separation in the levels of these biomarkers between affected patients and controls. Recently, new biomarkers have been proposed, like the alpha-secretase cleaved soluble amyloid precursor protein ectodomain. Some studies found reduced levels of this peptide in the cerebrospinal fluid of Alzheimer's patients, but it has been controversial as other researchers found opposite behaviours. These differences could arise from the lack of antibodies to specifically detect this cleaved product. Here, a new ELISA-like method is developed using a specific antibody to detect this peptide. The results show that the antibody has high specificity and can detect the cleaved peptide in human neural cells culture supernatant, in human cerebrospinal fluid and in serum. It was possible to detect a significant increase in cerebrospinal fluid of Alzheimer's patients and obtain better separation of affected individuals and controls compared to other methods. Overall, this method has the potential to be used in several applications both in basic research and clinical contexts to specifically measure a potential new biomarker for Alzheimer's disease.
A new sandwich immunoassay for detection of the α-secretase cleaved, soluble amyloid-β protein precursor in cerebrospinal fluid and serum
The IE from MS no longer understands current scripting languages, the latest main version (version 11) is from 2013 and has not been further developed since 2015.
Our recommendation: Use only the latest versions of modern browsers, for example Google Chrome, Mozilla Firefox or Microsofrt Edge, because only this guarantees you sufficient protection against infections and the correct display of websites!